drugset / Trial / NCT01630746

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

NCT01630746

Phase 3 Completed 19 enrolled Takeda
Treatment

Summary

The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.

Timeline

Start
2012-07
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 20 mg
Subject Vonoprazan Other / unclassified 40 mg

Indications